March 21, 2002New England Journal of Medicine2,713 citationsOpen Access
View Full PaperBosentan Therapy for Pulmonary Arterial Hypertension
Structured PICO
Does oral bosentan improve outcomes in patients with pulmonary arterial hypertension?
P
Population
Patients with pulmonary arterial hypertension
I
Intervention
Oral bosentan 125 mg twice daily
Oral bosentan at 125 mg twice daily is an effective and well-tolerated therapy for pulmonary arterial hypertension.
Abstract
The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.